Blood test to predict outcomes in MLL acute myeloid leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study uses a special blood test to see if it can predict which patients with a specific type of acute myeloid leukemia (AML with MLL changes) are more likely to relapse or have better survival. The test may help doctors plan better treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with acute myeloid leukemia (AML) with MLL rearrangement (a specific genetic change)
- You are between 6 and 60 years old
- You are receiving chemotherapy (cancer drugs) or planning to have a stem cell transplant
- You are able to follow study visits and procedures
- You do not have a medical condition that prevents you from receiving chemotherapy or stem cell transplant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a very sensitive blood test (digital PCR) to look for tiny amounts of leftover leukemia after a stem cell transplant, focusing on certain gene changes that are not the common fusion genes.
This study uses a special blood test (flow cytometry) to look for leukemia stem cells in your blood and bone marrow. The goal is to see if these cells can help predict if leukemia will come back after treatment, which might lead to better care for children and teens with AML.
This study looks at whether a simple blood test that measures tumor DNA (called ctDNA) can track how well treatment is working in children with acute leukemia. The goal is to see if the blood test can give the same information as a bone marrow test, which is more invasive.
This study looks at whether certain blood test levels (ferritin, and two ratios called CAR and AFR) can help predict how patients with a type of leukemia called AML (non-M3) will do. The goal is to find clues that may guide future treatment decisions.
This study is testing a blood test called AlloHeme that may help doctors predict whether your blood cancer will come back after a stem cell transplant. Joining this study could help you and your doctor monitor your recovery more closely.
This study looks at whether a simple blood test can help predict how well a person with a blood cancer like leukemia, lymphoma, or multiple myeloma might do. It aims to find a new biomarker that could guide treatment decisions.
Hear when a new Acute Myeloid Leukemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.